AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03421353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered as a 1-hour intravenous infusion either every three weeks (Q3W) or every four weeks (Q4W), depending on which arm the patient is enrolled in.~Durvalumab will be provided as a solution in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement.
Study NCT03421353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be infused over 30-60 minutes on Day 1.
Study NCT03421353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Flourouracil
Description: 5-flourouracil will be continuously infused over Days 1 to 4 every three weeks for up to 18 weeks.
Study NCT03421353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be infused over 30 to 60 minutes on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks.
Study NCT03421353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be infused over 30 minutes on Days 1 and 8 for up to 18 weeks.
Study NCT03421353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be infused over 30 to 40 minutes on Days 1, 8, and 15 for up to 18 weeks.
Study NCT00333840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon-alpha (INF-a)
Description: interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m\^2/day.
Study NCT00333840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine (ARA-C)
Description: cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.
Study NCT02754297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-Octreotate
Description: * The induction course will consist in 4 cycles at 8-10 weeks intervals.~* Concomitant amino acids will be administered for renal protection.~* Intra-arterial LuTate administration will be allowed in suitable cases.~* Dosimetry will be based on quantitative SPECT/CT imaging.~* In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles.
Study NCT00754572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv, every 4 weeks
Study NCT00754572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10-25mg oral or parenteral weekly.
Study NCT03544463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iNAP® Sleep Therapy System
Description: The iNAP® provides a pressure gradient within the oral cavity, which pulls the tongue toward the upper palate and pulls the soft palate forward in a way that enhances the patency of the upper airway near the pharynx so that upper airway patency can be maintained to prevent sleep-disordered breathing.
Study NCT04406454 — intervention group
Intervention type: DEVICE
Intervention: ApolloVue® S100 Image System
Description: The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 3 quality OCT images of B-scan (cross-section) and E-scan (en face) with 4 depths for each skin site respectively for each skin site. There is a total of 6 skin sites.
Study NCT00863304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab 10 mg
Description: tanezumab 10 mg one dose at weeks 0 and 8
Study NCT00863304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab 5 mg
Description: tanezumab 5 mg one dose at weeks 0 and 8
Study NCT00863304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: naproxen 1000 mg daily for 16 weeks
Study NCT00863304 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match tanezumab and naproxen dosing
Study NCT03405350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Redon-sulfide baths
Description: Encompassing whole body or isolated limbs - upper and/or lower limbs - temperature: 37-38 degrees Celsius, duration: 20 minutes.
Study NCT03405350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Mud Baths
Description: duration: 20 minutes, temperature 40-42 degrees Celsius
Study NCT03405350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotherapy
Description: It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min.
Study NCT03405350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Terrain Therapy
Description: walking, outdoors physical activities,
Study NCT03405350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Massage
Description: Depending on the needs of each patient it involved cervical (CC), thoracic (TH), or lumbar spine (LS).
Study NCT03405350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Therapy
Description: treatment parameters: sweeping, continuous, wavelength 808 nm, power 12 J, 400mV, duration 30s,
Study NCT03405350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low-frequency Magnetic Field
Description: duration 20 minutes, impulse shape - rectangular, induction 5 mT, frequency 20-50Hz,
Study NCT03405350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonotherapy
Description: treatment parameters: 800kHz/6cm2 head, ultrasound impulse wave: 2ms - impulse, 9ms - break, dose 0.5-0.6 W/cm2 over 6 minutes,
Study NCT03405350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: ventilator, treatment duration 2-3 minutes, temperature - 80 to - 110 degrees Celsius,
Study NCT03405350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy
Description: Bernard's diadynamic currents - treatment parameters: DF1 CP4 LP4, Nemec interference currents (frequency range 0-100Hz), percutaneous electrostimulation (TENS) - rectangular impulse currents, impulse duration 0.2ms, frequency 40Hz, regulated current 0-100mA,
Study NCT03405350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Light Therapy
Description: blue filter Sollux lamp, radiation distance 30-40 cm, duration 15 minutes, Bioptron lamp - radiation distance 10 cm, duration 5-10 minutes
Study NCT03007433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 400ml of Liquid Nutrient Drink
Description: 12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)
Study NCT02510586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: administer 1.0 MAC (1.7\~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed
Study NCT01656122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir
Description: Dosing of ABC will be according to the WHO guidelines by weight band for twice daily dosing. The once daily dosing will use the same mg/day as the twice daily dosing for that weight band
Study NCT01656122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3TC
Description: Dosing of 3TC will be according to the WHO guidelines by weight band for twice daily dosing. The once-daily dosing will use the same mg/day as the twice-daily dosing for that weight band
Study NCT03242447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Practice Self-Regulation
Description: e-PS-R utilizes 'blended learning', the combination of online and face-to-face instruction, and incorporates online videos and interactive elements that have been shown to be effective with high-risk youth. e-PS-R consists of eight 30-minute e-learning sessions for youth participants and four 30-45 minute one-on-one in-person meetings between youth and a trained facilitator.
Study NCT03242447 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Health Group
Description: The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes.
Study NCT04098588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BEAST
Description: See Arm Description
Study NCT04098588 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Descriptive Feedback
Description: See Arm Description
Study NCT01920113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine - remifentanil group
Study NCT01920113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol - remifentanil group
Study NCT01505088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg/mL Dexamethasone phosphate ophthalmic solution
Description: Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
Study NCT01505088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate (1%) Eyedrops
Description: Prednisolone acetate (1%) eyedrops
Study NCT01505088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mM sodium citrate buffer solution
Description: Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution
Study NCT01505088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Eyedrops
Description: Placebo Eyedrops
Study NCT03586921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Group Intervention
Description: The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party.
Study NCT03586921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
Study NCT01704157 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cryo-Touch III
Description: Study treatment at Day 0.
Study NCT01853280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-methylfolate
Description: 15mg/day L-methylfolate.
Study NCT01853280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS-Methylphenidate
Description: All subjects will be treated with open-label OROS-MPH
Study NCT01853280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OROS-Methylphenidate
Description: All subjects will be treated with open-label OROS-MPH
Study NCT01853280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mg matched placebo comparator, with open-label OROS-Methylphenidate
Study NCT01683812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Cup
Description: Study participants with dolichocephaly will be treated with the Cranial Cup for a minimum 12 hours per day.
Study NCT00333840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine (ARA-C)
Description: cytarabine 20 mg/m\^2/day (max 40 mg) SC for 10 days every month.
Study NCT03901651 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy with Retroview scope combing forward and retroflexed withdrawal technique
Description: Colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the standard colonoscopy findings.~The operator will record the polyps and adenoma encountered, describing the size and location.
Study NCT03901651 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy with standard colonoscope and forward withdrawal technique
Description: A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.~Each polyp and adenoma will be recorded, including the size and location.
Study NCT01975714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost
Study NCT01975714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free bimatoprost
Study NCT00875264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-11981 (kinase inhibitor)
Description: Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
Study NCT02293057 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VOICES Group
Description: VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
Study NCT02293057 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Girl Health Group
Description: The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
Study NCT01232777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.
Study NCT03373071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR T cell
Description: Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.~In case of toxicity, the patient will receive the dimerizing drug activating the suicide safety switch in order to improve the safety of the treatment
Study NCT01733784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induced central apneas
Study NCT01529242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine + Prednisolone
Description: Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
Study NCT01529242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine + Betamethasone
Description: Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
Study NCT04184544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improving of quality of care at health facility and outreach level
Description: Community Mobilization and engagement; Use of DHIS data for decision making; Capacity building of health care workers and providers and other Community level and facility level interventions to improve MNCH outcomes
Study NCT02221024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flushing with positive pressure
Description: Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)
Study NCT02221024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flushing with positive pressure
Description: Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)
Study NCT02221024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Study NCT02221024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Study NCT02221024 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MicroClave ICU Medica
Study NCT02221024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicroClave ICU Medica
Study NCT03845777 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Using Antiseptic solution
Description: Using of iodine including antiseptic solutions. The investigators investigate the urine iodine status of staff before and after the using of antiseptic solution
Study NCT00074984 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fabrazyme (agalsidase beta)
Description: 1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
Study NCT00074984 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg/kg placebo intravenously every 2 weeks
Study NCT02023593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Study NCT02236910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lu-DOTA-TATE
Study NCT01955564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-3509a
Description: single dose
Study NCT01436396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated dengue serotype 1, 2, 3, and 4 virus
Description: 0.5 mL, subcutaneous at age 12, 18, and 24 months
Study NCT01436396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine
Description: 0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
Study NCT01436396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella (MMR) vaccine
Description: 0.5 mL, subcutaneous at age 12 to 13 months.
Study NCT01436396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugated Vaccine
Description: 0.5 mL, intramuscular at age 13 to 14 months
Study NCT01436396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Pediatric Vaccine
Description: 0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
Study NCT01436396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine
Description: 0.5 mL, intramuscular at age 19 to 20 months
Study NCT01436396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated dengue serotype 1, 2, 3, and 4 virus
Description: 0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
Study NCT01436396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever Vaccine
Description: 0.5 mL, subcutaneous at age 12 to 13 months
Study NCT01436396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (NaCl)
Description: 0.5 mL, subcutaneous at age 12 to 13 months
Study NCT01436396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, mumps, and rubella vaccine
Description: 0.5 mL, subcutaneous at age 13 to 14 months
Study NCT02182739 — intervention group
Intervention type: DRUG
Intervention: Meloxicam
Description: tablets or injectable solution
Study NCT01554436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment
Description: The main criterion of evaluation of the smoking abstinence will be made by the measure of the rate of carbon monoxide (CO) in the expired air between the study start and during the study until 6 months after inclusion.~The secondary criteria of evaluation are criteria of neuropsychological order, namely the performances in the tests listed: result of NART test,Continuous Performance Test (CPT), Trail Making test, Stroop test, Iowa gambling task. (IGT), Hayling test, N back test, fluence verbal test
Study NCT03855865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel (prefilled syringe, weekly intravenous IV administration).
Study NCT03855865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine
Description: Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
Study NCT03855865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (prefilled syringe, weekly IV administration or oral daily).
Study NCT01573260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Argentinean Tango classes
Description: Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.
Study NCT01573260 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simple pamphlet about the exercise in PD
Description: Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.